Percheron Therapeutics regroups after clinical trial results; vows to ...
Jan 5, 2025 · Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has vowed to regroup and diversify its portfolio after some negative topline results from its Phase 2b trial of avicursen (ATL1102) in Duchenne muscular dystrophy (DMD), announced on December 18 last year. Plans to rebuild. In a letter to shareholders, members of the Percheron board acknowledged the shareholder and patient disappointment familiar ...
Biopharma’s struggles in 2024 could set stage for turnaround: …
Jan 9, 2025 · The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.
What's in store for Canada's economy in 2025?
Dec 24, 2024 · Canada's economy is expected to navigate a mixed landscape in 2025, as government policies and monetary easing provide some support, while elevated interest rates and trade uncertainties pose challenges, according to UBS analysts.
Rivian smashes Q4 delivery expectations with profitability in its ...
Jan 3, 2025 · Rivian Automotive Inc (NASDAQ:RIVN) blew passed expectations for its fourth-quarter production and delivery numbers, sending its shares nearly 22% higher on Friday morning. The electric vehicle (EV) maker is making progress in its bid for profitability and overcoming a critical component shortage that had hindered production.
MustGrow Biologics CEO on NexusBio acquisition; plans for 2025
Jan 3, 2025 · MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson talked with Proactive's Stephen Gunnion about the company's acquisition of NexusBio Ag assets from Univar Solutions Canada Ltd. Giasson emphasized the significance of this deal, highlighting how it transitions MustGrow from a pre-revenue company to one with substantial revenues. The acquisition includes an established sales ...
Tonix Pharmaceuticals achieves key milestone with FDA review …
Dec 24, 2024 · Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce an important milestone for the company’s New Drug Application (NDA) for a novel fibromyalgia treatment. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, marking the anticipated timeline for a decision on marketing ...
Copper, nickel and aluminum prices set to remain elevated amid …
Jan 2, 2025 · The outlook for base metals in 2025 is marked by tight market conditions and constrained supply, especially for copper, nickel and aluminum. Base metals appear to be better positioned due to the relatively tighter physical markets, analysts at Bank of America (BofA) and UBS have highlighted.
Eco Atlantic Oil & Gas boss says explorer is well placed to land ...
Nov 27, 2024 · The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.
Robinhood launches long-awaited desktop app | NASDAQ:HOOD
Oct 17, 2024 · The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.
Benchmark Metals Inc. (CVE:BNCH) Share Price | RNS News, …
In brief. Benchmark Metals Inc. is a mineral exploration company focused on advancing and developing the substantial resource potential of the Lawyer’s Gold-Silver Project, located in the prolific Golden Horseshoe of northern British Columbia, Canada.